These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

102 related articles for article (PubMed ID: 21723291)

  • 1. Whole-molecule antibody engineering: generation of a high-affinity anti-IL-6 antibody with extended pharmacokinetics.
    Finch DK; Sleeman MA; Moisan J; Ferraro F; Botterell S; Campbell J; Cochrane D; Cruwys S; England E; Lane S; Rendall E; Sinha M; Walker C; Rees G; Bowen MA; Schneider A; Liang M; Faggioni R; Fung M; Mallinder PR; Wilkinson T; Kolbeck R; Vaughan T; Lowe DC
    J Mol Biol; 2011 Aug; 411(4):791-807. PubMed ID: 21723291
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetics, dosimetry, and toxicity of the targetable atomic generator, 225Ac-HuM195, in nonhuman primates.
    Miederer M; McDevitt MR; Sgouros G; Kramer K; Cheung NK; Scheinberg DA
    J Nucl Med; 2004 Jan; 45(1):129-37. PubMed ID: 14734685
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A therapeutic anti-VEGF antibody with increased potency independent of pharmacokinetic half-life.
    Yeung YA; Wu X; Reyes AE; Vernes JM; Lien S; Lowe J; Maia M; Forrest WF; Meng YG; Damico LA; Ferrara N; Lowman HB
    Cancer Res; 2010 Apr; 70(8):3269-77. PubMed ID: 20354184
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Preclinical pharmacokinetics, interspecies scaling, and tissue distribution of humanized monoclonal anti-IL-13 antibodies with different IL-13 neutralization mechanisms.
    Vugmeyster Y; Szklut P; Tchistiakova L; Abraham W; Kasaian M; Xu X
    Int Immunopharmacol; 2008 Mar; 8(3):477-83. PubMed ID: 18279802
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Reduced immunogenicity and improved pharmacokinetics of humanized anti-Tac in cynomolgus monkeys.
    Hakimi J; Chizzonite R; Luke DR; Familletti PC; Bailon P; Kondas JA; Pilson RS; Lin P; Weber DV; Spence C
    J Immunol; 1991 Aug; 147(4):1352-9. PubMed ID: 1869828
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Correlation of pharmacodynamic activity, pharmacokinetics, and anti-product antibody responses to anti-IL-21R antibody therapeutics following IV administration to cynomolgus monkeys.
    Vugmeyster Y; Allen S; Szklut P; Bree A; Ryan M; Ma M; Spaulding V; Young D; Guay H; Bloom L; Leach MW; O'Toole M; Adkins K
    J Transl Med; 2010 Apr; 8():41. PubMed ID: 20420683
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Preclinical pharmacokinetics, interspecies scaling, and tissue distribution of a humanized monoclonal antibody against vascular endothelial growth factor.
    Lin YS; Nguyen C; Mendoza JL; Escandon E; Fei D; Meng YG; Modi NB
    J Pharmacol Exp Ther; 1999 Jan; 288(1):371-8. PubMed ID: 9862791
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetics of humanized monoclonal anti-tumor necrosis factor-{alpha} antibody and its neonatal Fc receptor variants in mice and cynomolgus monkeys.
    Deng R; Loyet KM; Lien S; Iyer S; DeForge LE; Theil FP; Lowman HB; Fielder PJ; Prabhu S
    Drug Metab Dispos; 2010 Apr; 38(4):600-5. PubMed ID: 20071453
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetics/dynamics of 5c8, a monoclonal antibody to CD154 (CD40 ligand) suppression of an immune response in monkeys.
    Gobburu JV; Tenhoor C; Rogge MC; Frazier DE; Thomas D; Benjamin C; Hess DM; Jusko WJ
    J Pharmacol Exp Ther; 1998 Aug; 286(2):925-30. PubMed ID: 9694951
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetics and pharmacodynamics of SB-240563, a humanized monoclonal antibody directed to human interleukin-5, in monkeys.
    Zia-Amirhosseini P; Minthorn E; Benincosa LJ; Hart TK; Hottenstein CS; Tobia LA; Davis CB
    J Pharmacol Exp Ther; 1999 Dec; 291(3):1060-7. PubMed ID: 10565825
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Anti-vascular endothelial growth factor receptor-1 antagonist antibody as a therapeutic agent for cancer.
    Wu Y; Zhong Z; Huber J; Bassi R; Finnerty B; Corcoran E; Li H; Navarro E; Balderes P; Jimenez X; Koo H; Mangalampalli VR; Ludwig DL; Tonra JR; Hicklin DJ
    Clin Cancer Res; 2006 Nov; 12(21):6573-84. PubMed ID: 17085673
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Reduced elimination of IgG antibodies by engineering the variable region.
    Igawa T; Tsunoda H; Tachibana T; Maeda A; Mimoto F; Moriyama C; Nanami M; Sekimori Y; Nabuchi Y; Aso Y; Hattori K
    Protein Eng Des Sel; 2010 May; 23(5):385-92. PubMed ID: 20159773
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Anti-CD74 antibody-doxorubicin conjugate, IMMU-110, in a human multiple myeloma xenograft and in monkeys.
    Sapra P; Stein R; Pickett J; Qu Z; Govindan SV; Cardillo TM; Hansen HJ; Horak ID; Griffiths GL; Goldenberg DM
    Clin Cancer Res; 2005 Jul; 11(14):5257-64. PubMed ID: 16033844
    [TBL] [Abstract][Full Text] [Related]  

  • 14. MEDI-563, a humanized anti-IL-5 receptor alpha mAb with enhanced antibody-dependent cell-mediated cytotoxicity function.
    Kolbeck R; Kozhich A; Koike M; Peng L; Andersson CK; Damschroder MM; Reed JL; Woods R; Dall'acqua WW; Stephens GL; Erjefalt JS; Bjermer L; Humbles AA; Gossage D; Wu H; Kiener PA; Spitalny GL; Mackay CR; Molfino NA; Coyle AJ
    J Allergy Clin Immunol; 2010 Jun; 125(6):1344-1353.e2. PubMed ID: 20513525
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetics and biodistribution of genetically-engineered antibodies.
    Colcher D; Pavlinkova G; Beresford G; Booth BJ; Choudhury A; Batra SK
    Q J Nucl Med; 1998 Dec; 42(4):225-41. PubMed ID: 9973838
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Muromonab CD-3: a review of its pharmacology, pharmacokinetics, and clinical use in transplantation.
    Hooks MA; Wade CS; Millikan WJ
    Pharmacotherapy; 1991; 11(1):26-37. PubMed ID: 1902291
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluation of an immunoassay for human-specific quantitation of therapeutic antibodies in serum samples from non-human primates.
    Stubenrauch K; Wessels U; Lenz H
    J Pharm Biomed Anal; 2009 May; 49(4):1003-8. PubMed ID: 19250787
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacokinetics and toxicology of immunotoxins administered into the subarachnoid space in nonhuman primates and rodents.
    Muraszko K; Sung C; Walbridge S; Greenfield L; Dedrick RL; Oldfield EH; Youle RJ
    Cancer Res; 1993 Aug; 53(16):3752-7. PubMed ID: 8339287
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Preclinical pharmacokinetics of Ranibizumab (rhuFabV2) after a single intravitreal administration.
    Gaudreault J; Fei D; Rusit J; Suboc P; Shiu V
    Invest Ophthalmol Vis Sci; 2005 Feb; 46(2):726-33. PubMed ID: 15671306
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Engineering of stable bispecific antibodies targeting IL-17A and IL-23.
    Mabry R; Lewis KE; Moore M; McKernan PA; Bukowski TR; Bontadelli K; Brender T; Okada S; Lum K; West J; Kuijper JL; Ardourel D; Franke S; Lockwood L; Vu T; Frank A; Appleby MW; Wolf A; Reardon B; Hamacher NB; Stevens B; Lewis P; Lewis KB; Gilbertson DG; Lantry M; Julien SH; Ostrander C; Chan C; Byrnes-Blake K; Brody J; Presnell S; Meengs B; Levin SD; Snavely M
    Protein Eng Des Sel; 2010 Mar; 23(3):115-27. PubMed ID: 20022918
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.